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Efficiency of the kidney disease outcomes quality
initiative guidelines for preemptive vascular access
in an academic setting
Traci A. Kimball, MD,a Ken Barz, MS,b Kelly R. Dimond, MD,a James M. Edwards, MD,c and
Mark R. Nehler, MD,a Denver, Colo; and Portland, Ore
Background:TheNational Kidney Foundation-KidneyDiseases OutcomesQuality Initiative (KDOQI) for vascular access
guidelines state that patients with late-stage chronic kidney disease (CKD) should undergo native arteriovenous fistula
(AVF) creation at least 6 months before anticipated start of hemodialysis (HD) treatments to obviate the need for other
vascular access types, such as grafts or central catheters.
Objective: The objective of this study was to determine the incidence of HD, the functional patency, and associated
morbidity of AVFs in patients with late-stage CKD placed according to KDOQI.
Methods: Consecutive patients with late-stage CKD who underwent AVF creation using KDOQI guidelines for anatomy
between January 2003 and December 2007 at two tertiary academic centers were retrospectively evaluated. Baseline
demographics, AVF type, and clinical comorbidities were recorded. Patients were stratified into one of four groups
(groups A-D) over the follow-up course based on two end points: patency of their AVF and whether or not they began
HD. The ideal primary outcome was AVF maturation and use for HD (group A; cumulative functional patency). Other
outcomes included AVF patency but no HD (group B), HD with AVF failure (group C), or no HD and AVF
abandonment (ie, death, refused hemodialysis, kidney transplant, or fistula failure; group D). Secondary outcomes were
time to first cannulation, complications, and secondary interventions.
Results: AVFs were created (46% forearm and 54% upper arm) in 150 patients with CKD (85% men, median age 63 years
old). At a median follow-up of 10 months, 74 patients (49%) were receiving HD and of these, 48 patients (65%) were
using their AVF (group A), whereas 26 patients (35%) were not due to fistula failure (group C). Thirty-four patients
(23%) never initiated HD treatments, but had a viable AVF (group B), and 42 patients (28%) never initiated HD and
abandoned their AVF (group D). Overall, AVF abandonment was 51%. Mean maturation time of all AVFs successfully
cannulated was 285 days (range, 30-1265 days). Complications encountered were maturation failure for cannulation
(15%), focal stenosis requiring intervention (13%), inadequate flows on HD (9%), steal syndrome (9%), and thrombosis
(8%). Cumulative functional patency for all AVFs was 19% and 27% at 6 and 12months, respectively, with a mean number
of two interventions per AVF (range, 1-10). Mortality during the study was 23%.
Conclusion:Despite successful creation andmaturation of a preemptive AVF in nearly two-thirds of patients who startedHD
during the follow-up and given the following observations: the high overall mortality of the population, the morbidity and
costs in secondary procedures of AVF creation, and the high incidence of abandonment, it is unclear if this strategy would
demonstrate a benefit in a randomized trial when compared to other access strategies. (J Vasc Surg 2011;54:760-6.)
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NChronic kidney disease (CKD) afflicts 14% to 16% of
the United States general population.1 Patients with CKD
are classified into one of five stages according to the pres-
ence of kidney damage/glomerular filtration rate. The
prevalence of CKD stages III to V has grown by 40% in the
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760ast decade.2 According to the National Kidney Founda-
ion’s Kidney Disease Outcomes Quality Initiative
KDOQI) for Vascular Access, patients in need of long-
erm, permanent access for hemodialysis (HD) should
ndergo native arteriovenous fistula (AVF) creation over
ther access types (eg, grafts or central catheters).3 This
hould be done preferably at least 6 months before the
nticipated start of HD, generally CKD stages IV and V.4
nce patients are identified, three key focus points in-
lude: avoid central catheterization; protect potential
ccess sites and conduit; and maximize the creation of
useable” fistulas as the best long-term access choice.
he guidelines emphasize targets for permanent HD
ccess placement to include a placement rate of func-
ional AVFs 50% in patients with incident HD and at
east 40% in prevalent cases; with long-term catheter use
n 10%.3 The Centers for Medicare and Medicaid
ervices embraced this idea with the development of the
ational Vascular Access Improvement Initiative
NVAII) and the Fistula First Breakthrough Initiative
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Volume 54, Number 3 Kimball et al 761(FFBI) to usher in these guidelines with the medical
community. The FFBI reset the fistula placement target
rate to 66% in patients with incident HD in 2009.4
Central to these initiatives is the presumption that
preemptive HD access planning will increase the likelihood
of fistula construction and successful maturation before
initiating HD treatments. Published reports about late
referral for vascular access evaluation demonstrate poor
global outcomes such as increased catheter use, increased
morbidity, such as line sepsis and central venous stenosis,
and ultimately increased mortality.5,6 Large portions of the
access practice guidelines for KDOQI, including the
NVAII and FFBI, are not significantly based on level 1 data.
Much of the literature on AVF placement has demon-
strated rather sobering results with maturation failure rates
of 40% to 45%,7-11 with a recent report of only 30%.12
Some patients undergoing AVF placement in this strategy
may never require HD and are exposed to unnecessary
morbidity. Examining the success of a preemptive AVF
construction strategy in accordance with KDOQI princi-
ples through a retrospective analysis at two academic cen-
ters focusing on these issues forms the basis of this report.
METHODS
Study design. Patients were identified by chart review
from the vascular surgery practices at the University of
Colorado at Denver (Denver Veterans AffairsMedical Cen-
ter and University of Colorado Hospital) and the Portland
Veterans Affairs Medical Center. Consecutive patients with
late-stage CKD who underwent preemptive AVF creation
(AVF before onset of HD per the NVAII and FFBI and in
accordance with KDOQI principles)2-4 between January
2003 and December 2007 were entered into a registry
database. Patients were excluded if they had a previous
vascular access procedure (eg, fistula, graft, or catheter),
were receiving HD treatments, or initiated HD within 1
week of the vascular access consultation (ie, HD vintage7
days). The database (Microsoft Access, Kent, Wash) was
Health Insurance and Portability Act compliant with de-
identified data and the study was approved by the human
research committees at both campuses. All patient data
were entered by one author (T. A. Kimball) and verified by
an additional author (K. R. Dimond).
Baseline demographics including age, gender, race,
body mass, smoking status (never, former, current), and
stage of CKD were reported. Comorbidities collected were
diabetes, hypertension, and coronary artery disease. Tech-
nical operative data included preoperative vein mapping
and type of AVF created. Preoperative vein mapping data
included the cephalic and basilic veins above and below the
elbow. Adequate vein size for AVF creation was qualified as
2.5 mm per the recommended guidelines by Silva et al.13
The radiocephalic AVF was considered as the first-line
option if the cephalic vein size was adequate. Additional
prognostic indicators such as arterial blood velocity and
resistive indexes were not abstracted.
The primary objectives were to determine the efficiency
of a preemptive AVF strategy by examining over time the ruccess of predicting the need for HD and success of AVF
aturation/use. To accomplish this, patients were strati-
ed into one of four subgroups (groups A-D) over the
ollow-up period: those onHDusing their fistulas (group A
ideal result), those not on HD with patent fistulas (group
– second best result), those on HD with a secondary
ccess type (failed fistula; group C – third best result suc-
eeded in predicting HD but failed in AVF maturation and
unction), and those not on HD with an abandoned fistula
ue to death, refusal of hemodialysis, kidney transplant, or
stula failure (group D – failed on both goals). To validate
ur compliance with the KDOQI guidelines for establish-
ng HD access, we quantified the fraction of patients who
eceived preoperative vein mapping before the fistula cre-
tion and median referral time before the creation of the
stula.
Patient-related outcomes determined over the fol-
ow-up period included incidence of HD initiation and
ll-cause mortality. Fistula-specific outcomes assessed were
ean maturation time (ie, time interval from creation to
rst cannulation), cumulative functional patency at 6 and
2 months, mean number of interventions per fistula, most
requent complications, and total AVF abandonment over
ime.
Statistical analysis. Baseline characteristics were sum-
arized, with categorical and continuous variables. Data
re presented as mean  SD or percentage of total time-
ependent, Cox-proportional-hazard models were con-
tructed to estimate survival from abandonment with age,
ody mass index (BMI), smoking status, institution, race,
nd fistula type as the dependent variables. Continuous
ariables such as age and BMI were categorized as age75
r age 75, and BMI 30 or BMI 30. Log-rank tests
ere used to compare curves in accordance with accepted
eporting standards.14 A probability .05 was considered
tatistically significant. All analyses were conducted using
AS, version 9.2 (SAS Institute, Cary, NC).
ESULTS
Demographics. The study cohort included 150 pa-
ients with late-stage CKD (85%men, median age 63 years)
eferred for first-time AVF creation over a 4-year period at
he combined sites (Portland Veterans AffairsMedical Cen-
er, Denver Veterans Affairs Medical Center, and Univer-
ity of Colorado Hospital). Table I lists baseline demo-
raphics and clinical characteristics of the study group.
ost patients were white (66%) with African American
15%) and Hispanics (11%) comprising the largest two
inority groups.
The majority of patients referred were CKD stage IV.
ver two-thirds of patients were diabetic and 70% had
moked. Consistent with the high incidence of diabetes in
his population, patients were frequently obese with a me-
ian BMI of 30. The cohort was reasonably efficient in
ollowing the guidelines with 142 patients (92%) undergo-
ng preoperative vein mapping. The median referral time
as 31 days (range, 1 to 400 days) although that only
eflected the time from the consult to AVF placement and
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September 2011762 Kimball et aldoes not take into account delays from patient-related
issues such as agreeing to undergo HD and presenting for
surgical consultation. One hundred fifty AVFs were created
(54% in upper arm and 46% in the forearm). Themajority of
forearm AVFs were constructed at the Portland Veterans
Affairs Medical Center and most basilic vein transpositions
were constructed in Denver (Table II).
Patient-related outcomes. At a median follow-up of
10 months (Fig 1), 74 patients (49%) were receiving HD
and 48 patients (65%) were using their AVF (group A),
whereas 26 patients (35%) were not due to fistula failure
(group C). Thirty-four patients (23%) never initiated HD
Table I. Demographics of 150 patients with chronic
kidney disease undergoing preemptive arteriovenous
fistula construction
Variable n Percent
Smoking
Current 36 23
Former 75 48
Never 45 29
Diabetes 104 69
Hypertension 100 67
Median BMI 30 –
CKD
Stage III 7 5
Stage IV 108 73
Stage V 34 23
BMI, Body mass index; CKD, chronic kidney disease.
Table II. Type of pre-emptive arteriovenous fistula
constructed
AVF type n Percent
Forearm 72 48
Upper arm 78 52
Brachial cephalic 58 74
Basilic vein transposition 20 26
AVF, Arteriovenous fistula.
Fig 1. Clinical fate at a mean of 10 months of 150 patients with
chronic kidney disease undergoing preemptive arteriovenous fis-
tula construction. AVF, Arteriovenous fistula; HD, hemodialysis.treatments, but had a patent AVF (group B) and 42 pa- aients (28%) never initiated HD and abandoned their AVF
group D). Thirty-four (23%) of all patients had died.
Fistula-specific outcomes. Mean maturation time of
ll AVFs that were cannulated was 285 days (median, 185
ays; range, 30-1265 days). Cumulative functional patency
or all AVFs which was 19% and 27% at 6 and 12 months,
espectively, with a mean number of two interventions per
VF (range, 1-10). The top five complications encoun-
ered were maturation failure for cannulation (15%), focal
tenosis requiring intervention (13%), inadequate flows on
D (9%), steal syndrome (9%), and thrombosis (8%). A
ime-dependent, Cox proportional-hazardmodel found no
nfluence from patient and operative predictor variables on
ime to AVF abandonment (Table III). Upper extremity
stulas were abandoned less often than forearm fistulas
uring the short-term (2 years), although this compari-
on was not statistically significant over the entire time
nterval (Fig 2; P  .872). The overall AVF abandonment
ncidence was 51%.
ISCUSSION
The present series of preemptive AVF construction is
elatively consistent with most7-11,15,16 but not all12 recent
VF reports. At slightly 1 year, approximately two-third
f patients had a successful strategy – alive using their AVF
or HD. One-third of patients had a partially successful
trategy – alive with patent AVFs but they were not yet on
D. The remainder died or abandoned their AVF with or
ithout initiation of HD. Over 90% of the AVFs under-
ent preoperative venous ultrasound scanmapping.Half of
he AVFs created were in the forearm and the remainder
bove the elbow. The mean maturation time was quite
ong, but that is a function of timing of the need for HD as
uch as cannulation issues. The cumulative functional
atency for the series was quite low at 6 and 12 months,
lso partially reflective of timing of HD.
The possible reasons for these poor results are likely
ultifactorial. Using size criteria alone for determining
dequate venous anatomy likely misses other important
eatures of the vein, including prior injury from venous
able III. Time dependent, Cox-proportional-hazard
odel for variables potentially influencing time from
rteriovenous fistula abandonment
Test of equality over strata
Strata Test 2 DF P value
ender Log-rank 0.5065 1 .4767
ace Log-rank 0.3751 1 .5402
moking Log-rank 0.5717 1 .4496
nstitution Log-rank 3.9371 2 .1397
ge 75 Log-rank 0.0163 1 .8984
MI 30 Log-rank 0.1938 1 .6598
rocedure Log-rank 2.5937 5 .7623
istula location Log-rank 0.0256 1 .8729
MI, Body mass index; DF, degrees of freedom.ccess. Prior injury can then lead to robust fibrointimal
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Volume 54, Number 3 Kimball et al 763hyperplasia and AVF failure once the vein is arterialized.
There may be other systemic factors in play that contribute
to poor AVF maturation such as diabetes.
Do these results justify a preemptive HD access strat-
egy? In comparison to other prophylactic treatment strate-
gies in vascular surgery – abdominal aortic aneurysm (AAA)
repair17,18 and asymptomatic carotid revascularization19 –
the strategy success in the current series is lower. Even
taking into account that the natural history of many pa-
tients with asymptomatic AAA and carotid stenosis is to
remain so, the long-term success of the revascularizations is
markedly better than the success rate of AVFs. Only half of
the preemptive AVF population benefits from the proce-
dure with intermediate term patency. However, the argu-
ment can be made that the perioperative risk of the AVF is
less than AAA repair or carotid revascularization.
Comparing preemptive AVF construction with opera-
tive management of small AAAs before the major random-
ized trials17,18 is instructive. The assumption for small
AAAs was that all patients became worse operative risks
over time. Furthermore, it was established that small AAAs
would grow over time and that rupture risk was related to
increased size. Therefore, it made intuitive sense to operate
on good risk patients with small AAAs provided the repair
could be done with a small perioperative mortality risk.
These assumptions, however, were not confirmed when
tested in randomized trials using open17,18 or endovascu-
Fig 2. Freedom from abandonment of 150 preemptive
.827).lar20 techniques despite excellent technical success. mPre-emptive AVF construction is similar in many ways.
he assumption is that patients become worse access can-
idates over time as potential vein sites are exhausted with
ntravenous lines. It is established that central venous cath-
ters have significant septic and thrombotic morbidity21
nd once patients initiate HD with a central catheter they
ave increased mortality rates22 and are often reluctant to
gree to surgery for a better access option. Patients with
hronic kidney stages IV and V have a high rate of requiring
ear-termHD,23 and thematuration time for AVFs is often
easured in months not weeks. Therefore, it makes intui-
ive sense to construct AVFs preemptively on patients with
ate-stage CKD.
However, there are some major qualifying points
ith this argument. As stated above, global success of
VF construction in the vast majority of recent reported
eries7-11,15,16 is modest (50% despite preoperative assess-
ent per KDOQI) including one randomized trial. One
ajor principal of prophylactic vascular care is to focus on
ood risk patients with a life expectancy that justifies the
p-front morbidity and potential mortality of the proce-
ure. Unfortunately, the mortality rate of a modern renal
ailure population is substantial (patients over 60 years of
ge have a survival similar to advanced stages of malig-
ancy).1,24 The quality of life of many patients on HD is
uestionable as withdrawal of HD is a major cause of death
n the United States Renal Data report and escalates
venous fistulas comparing upper arm and forearm (P arterioarkedly with population age.1 Just as patients are re-
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September 2011764 Kimball et alluctant to undergo surgery for an AVF once they have
catheter-based, central access on HD, they are also often
reluctant to undergo surgery for an AVF when their
CKD does not yet require HD.
The argument for preemptive AVF construction would
be much stronger if the success rate of the procedure was
improved. Although there is no general agreement, per-
haps our criteria for acceptable venous conduit are not
stringent enough. In this study, veins 2.5 mm or greater
were considered usable for AVF construction as recom-
mended by Silva et al.13 However, this differs from the best
report on lower extremity venous bypass, the Project or
Ex-Vivo vein graft Engineering via Transfection III trial.25
In that study, a venous conduit of3.5mmwas considered
high risk26 and those grafts had worse patency rates and
greater number of interventions compared to grafts con-
structed with venous conduit3.5 mm. A recent report on
AVF construction demonstrated that veins 4 mm had
much better maturation rates.12 Unfortunately, in our
practice, very few patients would qualify for an attempt at
preemptive AVF construction if those criteria were used;
but a 3.5 mm vein requirement could be a compromise.
One of the authors in the present report uses3mm rather
than 2.5 mm as the size for acceptable venous conduit for
AVFs.
The current series is not adequately powered to deter-
mine if predictor variables such as demographics, site, dia-
betes mellitus, BMI, or location of AVF above or below the
elbow influenced the success of the preemptive AVF strat-
egy. None of these variables showed an influence, but that
could represent a type II error. Diabetes has been shown in
other studies to have a negative impact on success of
forearm AVFs.16,27 Interestingly, there was a trend toward
lower, near-term (2 years) abandonment rates for upper
extremity fistulas when compared to forearm fistulas; how-
ever, over the entire time interval there was no difference in
freedom from abandonment by location of the AVF. In the
current series, one site constructed AVFs in the forearm
much greater than the other sites, but this did not seem to
influence success. Other weaknesses of the current study
include the retrospective nature, the inclusion of just two
centers, a predominately male population, few African
American patients, and not including the actual size of the
veins in the database for separate analysis.
Finally, it is important to recognize the regulatory
and economic issues involved in the current push toward
preemptive HD access. The Center for Medicare and
Medicaid Services has just passed new payment rules
involving quality improvement measures to take effect in
2012.28 The initial measures will involve anemia man-
agement and adequacy of HD. However, future mea-
sures will involve HD access and presumably a reduction
in reimbursement for the use of central catheters either
individually or beyond a percent threshold at the center.
This will create financial incentive for increased preemp-
tive AVF placement.
1ONCLUSION
The results of the present study in combination with
ecent AVF reports confirm that preemptive AVF construc-
ion in patients with CKD stages IV and V has merit if the
utcome of concern is the percent of patients with incident
D who use the AVF. However, given the high overall
ortality of the population, the morbidity, and costs in
econdary procedures of AVF creation, and the high inci-
ence of abandonment, it is unclear if this strategy would
emonstrate a benefit in a randomized trial when compared
o other access strategies.
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Dr Samuel Eric Wilson (Long Beach, Calif). When a piece of
shrapnel, a stab to the groin, or an errant orthopedic drill can
produce an arteriovenous fistula (AVF), it occurred to some, that
vascular surgeons working in a modern operating room, aided by
magnification and 6-0 sutures, could construct a functioning AVF
almost all the time. In fact, a review of the literature does show
some case series of highly selected patients in whom the individual
surgeon using a unique technique known only to him or her can
have very high rates of AVF success. In the half million North
Americans with end-stage renal disease (ESRD), however, these
results cannot be confirmed and approximately 50% of AVFs never
function.
Our colleagues from Denver and Portland have demonstrated
that when AVFs were constructed preemptively, in anticipation of
hemodialysis, 23% of patients had never used the fistula for hemo-
dialysis at a median follow-up period of 10 months. Analysis of
these 34 patients would be worthwhile to see why they did not
proceed to hemodialysis, for example, was the creatinine too low?
Was the degree of renal failure acted upon at the time of fistula
placement accentuated by a transient but reversible event? Or was
the nephrology team slow in initiating hemodialysis? Clinical judg-
ment can vary here, and we depend on nephrologists to time the
initiation of hemodialysis. Do the authors know if any of these 34
patients have actually begun hemodialysis in the intervening
months since submission of the abstract?
The Kidney Disease Outcomes Quality Initiative (KDOQI)
guidelines have generated more interest in vascular access surgery
which was formerly an “orphan” area. A quick look at PubMed
shows 1850 articles in the last 20 years on hemodialysis and AVF
with 1400 published in the last 10 years. The authors have met the
goals stated by the NKF KDOQI guidelines (2006 update) of
having a prevalent, functional AV placement rate of greater than
65% (48 of 74) in the patients who did begin dialysis via the index
AVF. Many surgeons have experienced lower prevalence rates ino read the 2009 report from the United States Renal Data System
Foley RN, Chen SC, Collins AJ. Hemodialysis access at initiation
n the United States, 2005-2007. Hemodial Int 2009;13:533-42)
n which the proportion of patients initiating dialysis via an AVF
as only 13.2%. In fact, an astounding 63% of patients were
eceiving dialysis via a catheter alone. Worse still, the mortality rate
or patients with catheter alone was twice that for patients who had
n AVF.
After a review of 20 years of technological innovations in
emodialysis, Lameire et al (Clin J SocNephrol 2009;Suppl 1:S30-
0) concluded that these had not been translated into longer
atient survival and identified only pre-dialysis care and timely
reation of the AVF as themost effective strategy for improving the
ong-term outcome of the patient on dialysis. Accordingly, I
elieve that the 23% of patients who had a patent but not yet
ccessed AVF at 10 months should not be viewed as failures,
ecause in subsequentmonths the patients may well use this access.
What can we do to increase the number of AVFs that mature
or satisfactory vascular access and extend functional patency?
lmost all the authors’ patients had preoperative venous mapping.
Although I view this as being indispensible in the obese
atient or in the brachium to establish the diameter of the basilic
ein in the forearm, it does not seem to add much to a careful
hysical examination. I find that the AVF constructed in the
ntecubital fossa (brachiocephalic) has a more predictable out-
ome than the radiocephalic fistula. In the older patient, a vein
ransposition does not offer much advantage over a brachioaxillary
olytetrafluoroethylene (PTFE) graft in patency and carries the
isadvantage of an average 5 months of maturation time. After the
stula is established, surveillance with ultrasound scan to identify
reas in which balloon-assisted maturity may improve flow, is a
seful strategy. Because needle puncture injury is a prominent
ause of AVF thrombosis, education of dialysis technicians may
ield dividends.In summary, I suggest that the patients not on dialysis by 10
onths should not be viewed as unsatisfactory, because hemodi-
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September 2011766 Kimball et alalysis may be inevitable and there is little disability to having the
AVF in place. Certainly, effort should be directed at developing
predictors for onset of hemodialysis perhaps linking patterns in the
creatinine clearance with the etiology of chronic kidney disease
(CKD). The KDOQI guidelines may be difficult to achieve, but
remember the KDOQI disclaimer explicitly states that the clinical
practice guidelines “are not intended to define a standard of care
and should not be construed as one.”
Dr Traci A. Kimball. Dr Wilson, thank you for your ques-
tions and for providing us with a copy of your discussion in lead of
the meeting allowing us to prepare our rebuttal with some fore-
thought.
In response to your first series of questions, the majority of
patients in this series had CKD stages IV and V, and therefore
glomerular filtration rates (GFRs) 30 mL/min/m2. Within the
nephrology literature, progression to ESRD is eminent at these
stages. It would be interesting to look at the subgroup of patients
not yet on hemodialysis to determine if they did in fact have less
severe CKD than those who progressed to hemodialysis (HD). I
should reiterate that initiation to HD is not entirely dependent on
the absolute value of one’s GFR, but also depends on a patient’s
willingness to start treatments, so this natural history is multifac- gorial. Your second question was whether there existed a trigger
hat determined the access referral. I submit that I am unable to
ake any conclusions as to the circumstances behind the referral by
ephrology. However, I can conclude that for the most part our
urgeons do not routinely question the necessity of fistula place-
ent.
As for the 34 patients not yet on HD with patent fistulas, we
ould have to re-open our data set and extend the follow-up
eview beyond our end date, December 2007. The answer would
hen depend on the completeness of the medical record.
Finally, in our surgeons’ hands, AVF placement and functional
uccess met the accepted KDOQI standards; however, this report
escribes a predominant VA population, which implies that pa-
ients are referred from a large catchment area making it impossible
o follow each and every patient longitudinally. Whereas educating
ach patient’s dialysis unit about proper fistula handling would be
he ideal, it is just not feasible with the number of patients receiving
stulas. We do not practice routine surveillance and balloon-
ssisted maturation so I cannot comment about these practices and
hether they improve outcomes.Thank you again for your questions. Thank you to the pro-
ram committee for the opportunity to present this work.
